GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together.
This partnership will provide GSK with access to our advanced computational biology, cellular and perfused human organ platforms to generate proprietary human liver datasets. The data will be used by both GSK and Ochre Bio to build better AI models – allowing for fewer, but more precise, experiments to aid in target choice.
The deal has a total value of up to $37.5m for both co-exclusive and non-exclusive data licences.
Jack O’Meara, Co-founder and CEO at Ochre Bio, said:
“Data innovation is as important as algorithmic innovation when investing in ML workflows. Both Ochre Bio and GSK share a commitment to providing liver disease patients with more effective medicines, and believe in a data-driven approach to improve therapeutic discovery. These large-scale, causal human datasets will be foundational for our respective liver R&D pipelines.”
Kim Branson, SVP, Global Head of AI and Machine Learning at GSK, said:
“In addition to our programs in MASH to hepatitis B, we are committed to addressing unmet need in liver disease by generating unique data in human derived systems. Ochre Bio’s platform will provide GSK with foundational data sets to create AI models allowing us to better understand liver function and disease for the development of novel medicines.”
Read the full announcement here.
